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challenges. Self-administered questionnaires were used and data were analyzed 
with SPSS version 16. Results: The mean age was 16.9 ± SD 2.5 and 21 (62%) were 
mainly females and in school. Four were in primary school, 14 in junior secondary 
school, 12 in senior secondary and another 4 in tertiary institutions. Most (85%) 
were aware that young people their age could fall sick, 91% had heard of HIV, 70% 
knew someone with HIV and 45 % thought that adolescents were not at risk of HIV. 
Eighteen (52.9%) knew their HIV status, 17 (50%) were on antiretroviral and 32% of 
these admitted to missing Anti-Retroviral (ARVs) dose. ConClusions: Disclosure 
of HIV status to adolescents and young people is dependent on a complex mix of 
factors and most practitioners recommend an age and developmentally appropriate 
disclosure. The knowledge and awareness of HIV was 91%. There is also the need to 
support care givers to disclose HIV status and to support young people to adhere to 
ARVs for better outcomes. KeywoRds: Knowledge; Disclosure Adolescents/Young 
Adults; HIV, Ghana.
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objeCtives: The health care system of Ukraine is being transformed according to 
the modern world format. More and more doctors are aware of the need for the use 
of technologies based on evidence-based medicine, particularly in the management 
of hepatitis C. Methods: In 2013 the multidisciplinary working group involving 
professionals and patients developed an adapted clinical guideline, based on HTAs 
and strategies of evidence-based medicine on the treatment of hepatitis C, and uni-
fied clinical protocol “Viral hepatitis C”. Results: The differences in the treatment 
of hepatitis C in Ukraine compared to the best international practice were revealed 
and considered while developing medical and technological documents for health 
care in hepatitis C. Doctors and the public were informed of modern evidence-based 
technologies concerning management of the hepatitis C. As a result, the multidis-
ciplinary working group adapted these documents of best methodological quality. 
Introduction of these documents reorients doctors on a modern approach to the 
assessment of scientific medical information. The unified clinical protocol contains 
provisions for minimum acceptable quality of primary and specialized medical care 
and the algorithms of patient’s identification. ConClusions: Provision of changes 
in the current medical practice is associated with the introduction of modern medi-
cal technologies based on evidence-based medicine. Ukraine has implemented the 
algorithm for the use of best practice: a multidisciplinary working group adapts 
clinical guidelines based on evidence → creates unified clinical protocols → each 
health institution develops local protocols, taking into account the resources of a 
health facility and interaction of these institutions.
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objeCtives: The prevalence of the hepatitis C virus (HCV) remains high amongst 
people who inject drugs (PWID) and accounts for the majority of newly acquired infec-
tions. This study aims to quantify the value of treatment amongst PWID with new 
direct acting antivirals (DAAs) at increased uptake rates, with respect to the avoidance 
of future infections and subsequent long-term complications of HCV. Methods: A 
dynamic HCV transmission and disease progression model was developed, incorpo-
rating acute and chronic infection and their long-term complications (decompensated 
cirrhosis, cancer, liver transplant and mortality), with the potential for reinfection 
following treatment failure. The model was populated with prevalence and therapy 
data from a UK setting. Scenarios of current standard of care (SoC) treatment efficacy 
and uptake were compared to anticipated sustained virologic response (SVR) rates 
of 90–100% and increased uptake over varied horizons. Results: SoC led to modest 
reductions in prevalence; > 5% after 200 years. New treatments achieving 90% SVR 
could reduce prevalence below 5% within 60 years at current uptake rates or within 5 
years if all patients are treated. Amongst 4,240 PWID, chronic HCV infections avoided 
as a result of increasing treatment uptake over the period 2015–2027 ranged from 
20–580 and 34–912 with SoC and 90% SVR rates respectively. The reduction in down-
stream HCV infections due to increasing treatment uptake resulted in an approximate 
discounted gain of 300 life-years (from avoiding reduced life expectancy from HCV 
infection) and a gain of 1,700 QALYs (from avoiding the disutility of HCV infection 
and related complications), with a projected £5.4 million cost saving. ConClusions: 
While improved SVR profiles led to reductions in modelled prevalence, increased 
treatment uptake was the key driver of future infections avoided. Increased treatment 
among PWID, with new more efficacious therapies, could significantly change the 
future dynamics, cost and health burden of HCV-related disease.
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objeCtives: Poor adherence to treatment guidelines undermines the goals of 
malaria treatment with implications for worsening malaria burden. This study 
analyzed the diagnostic and prescription practices for uncomplicated malaria at 
two levels of public health facilities in Nigeria, to assess the current state of compli-
ance to policy. Methods: Retrospective audit of patients’ records for uncompli-
cated malaria was carried out at a primary/secondary and tertiary health facilities. 
Demographics, diagnostic information, medication and cost data were extracted. 
Data from the two facilities were analyzed and compared for similarities and 
monitor and to correlate HRQL improvements in patients undergoing different 
treatment strategies.
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objeCtives: In ATTAIN, a Phase III, randomised, head-to-head comparison study 
of simeprevir versus telaprevir, both with peginterferon/ribavirin (PR), in HCV gen-
otype 1-infected prior null or partial PR responders, simeprevir exhibited better 
safety and tolerability. In this analysis, the impact on patient-reported outcomes 
(PRO) was analysed. Methods: Patients received simeprevir (150mg QD) or tel-
aprevir (750mg TID, 7-9hrs apart) +PR for 12wks followed by PR alone (36wks) in 
a double-blind, double-dummy design. PRO questionnaires, completed at base-
line, throughout treatment and at follow-up, rated fatigue severity (FSS), depres-
sive symptoms (CES-D), work and daily activities impairment (WPAI: Hepatitis-C), 
health-related quality of life (EQ-5D visual analogue scale), and skin symptoms 
(Skindex-16). During simeprevir/telaprevir treatment, between-treatment mean-
value differences were calculated using area-under-the curve to Wk12 (AUC12) for 
all measures except Skindex-16 where maximum (worst) scores during the first 12 
wks were used. Subgroup analyses evaluated the impact of SVR12, age, fibrosis and 
treatment completion. Results: Compared with normative studies, baseline PRO 
scores indicated greater fatigue, depressive symptoms and daily activities impair-
ment. Mean PRO scores in both groups worsened during the first 12 weeks of treat-
ment, remained stable through Week 48 and returned to values close to baseline at 
end of treatment. Clinically relevant between-treatment differences in FSS, CES-D, 
Skindex-16 and EQ-5D scores indicated less impairment with simeprevir than tel-
aprevir. AUC12 between-treatment differences significantly favoured simeprevir 
for FSS (p= 0.003), WPAI Activity Impairment (p= 0.022), and EQ-5D (p< 0.001). Mean 
Skindex-16 maximum total (p= 0.0087) and subscale scores were significantly lower 
for simeprevir. Subgroup analyses showed less impairment with simeprevir versus 
telaprevir on most PRO scores in patients who failed treatment, were > 45 years old 
or had advanced fibrosis. ConClusions: Simeprevir/PR resulted in less fatigue, 
depressive and skin-related symptoms and less impairment in daily activities than 
telaprevir/PR. These findings provide valuable information on the tolerability of 
these regimens from the patient perspective.
PIN103
satIsfactIoN of hIv PatIeNts wIth PhaRmacy seRvIces IN south 
easteRN NIgeRIaN hosPItals
Ekwunife O.I.
Nnamdi Azikiwe University, Agulu Campus, Nigeria
objeCtives: The greatest burden of the HIV infection is felt in sub-Saharan Africa. 
Nigeria is rated among the first three largest countries with HIV population. 
Pharmacists play an important role in the care of HIV patients especially by provid-
ing pharmaceutical care. Thus it is imperative to assess the experience and satisfac-
tion of HIV patients with the pharmaceutical services they receive as this will ensure 
that quality care is rendered. The objective of this study was to assess HIV-infected 
patients’ satisfaction with pharmacy services provided in South-Eastern Nigeria’s 
HIV/AIDS clinics. A secondary aim was to repeat the validation process in order to 
confirm the initial validation of PSPS questionnaire. Methods: The survey was 
conducted in 6 HIV/AIDS clinics in South-Eastern Nigeria. Multi-stage sampling 
technique was used to select the clinics. Re-validation techniques employed include 
factor analysis, reliability test, and construct validity. The level of satisfaction of the 
participants was determined. Variance in satisfaction score among the different 
demographic variables was also assessed. Results: The response rate was 81.85%. 
The Cronbach alpha value was 0.84. The 16 items of PSPS questionnaire resolved 
into 4 factors as established by the initial validation exercise. Re-validation of the 
PSPS Questionnaire’s construct revealed the same result obtained in the original 
validation as items that were related showed convergence while items that were 
not related showed divergence. With the exception of item 12, the average score 
obtained in the survey was high. Most of the average scores ranged from 4 to 5, 
signifying that responses ranged from agree to strongly agree. ConClusions: HIV 
patients were highly satisfied with services rendered by the pharmacists in South-
Eastern HIV clinics in Nigeria and PSPS proved to be a reliable and valid instrument 
for measuring satisfaction of HIV patients with pharmacy services.
INfectIoN – health care use & Policy studies
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objeCtives: In Ghana it is estimated that 1.7% of HIV infections occur in young 
people aged 15-24. Despite this the representation of young people in our clinics is 
small. Adherence to treatment, appointment keeping and knowledge of HIV status 
remain a challenge. Disclosure has been shown to confer the following benefits. 
The study sought to assess the knowledge of HIV status of adolescents and young 
adults. Methods: A baseline study was conducted to ascertain if adolescents and 
young adults knew their HIV status and also determine their knowledge on HIV in 
general with 34 participants. An adolescent club was established to engage with 
young people, provide better tailored care and support and to solve their peculiar 
